A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Inclusion Criteria: * ECOG score 0-1 * ER\>10%, PR\>10%, HER2(0)/HER2(1+)/HER2(2+) and no amplification of FISH * BRCA1/2 gene mutation * No other site metastases were detected by imaging evaluation after surgical treatment * Non-PCR breast cancer after neoadjuvant therapy, or breast cancer with postoperative pathology indicating ≥pN2 * The patient had no major organ dysfunction Exclusion Criteria: * Allergic to the investigational drug, inability to take the drug orally, or refusal of the medication regimen * Has been enrolled in another study or has been discontinued for less than or equal to 4 weeks * There is serious dysfunction of vital organs (heart, liver, kidney) * Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years * In other acute infectious disease or chronic infectious disease activity period * A history of uncontrolled seizures, central nervous system disorders, or mental disorders * There is a known history of human immunodeficiency virus